Hsd11b2 haploinsufficiency in mice causes salt sensitivity of blood pressure

Hypertension

Volumn 57, Issue 3, 2011, Pages 515-520

  Bailey, Matthew A ^a,d   Craigie, Eilidh ^a   Livingstone, Dawn E W ^a   Kotelevtsev, Yuri V ^a,c   Al Dujaili, Emad A S ^b   Kenyon, Christopher J ^a   Mullins, John J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b QUEEN MARGARET UNIVERSITY   (United Kingdom)

^c PUSHCHINO STATE UNIVERSITY   (Russian Federation)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

genetics; hypertension; kidney; renal; sodium

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; CORTICOSTERONE; MINERALOCORTICOID RECEPTOR; SODIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; ENZYME ACTIVITY; GENE MUTATION; HEART WEIGHT; HETEROZYGOSITY; HIGH SODIUM INTAKE; HYPERTENSION; HYPOKALEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SODIUM EXCRETION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ANALYSIS OF VARIANCE; ANIMALS; BLOOD PRESSURE; HAPLOINSUFFICIENCY; HORMONE ANTAGONISTS; HYPERTENSION; MICE; MIFEPRISTONE; MUTATION; POLYMORPHISM, GENETIC; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SODIUM CHLORIDE, DIETARY;

EID: 79953244366     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.163782     Document Type: Article

References (36)

1. Weinberger MH, Fineberg NS, Fineberg SE, Weinberger M. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension. 2001;37:429-432. (Pubitemid 32199006)
2. Morimoto A, Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, Inenaga T, Kimura G. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet. 1997;350:1734-1737. (Pubitemid 28036672)
3. Jaimes EA, Zhou MS, Pearse DD, Puzis L, Raij L. Upregulation of cortical COX-2 in salt-sensitive hypertension: role of angiotensin II and reactive oxygen species. Am J Physiol Renal Physiol. 2008;294: F385-F392. (Pubitemid 351199404)
4. Chai W, Danser AH. Why are mineralocorticoid receptor antagonists cardioprotective? Naunyn Schmiedebergs Arch Pharmacol. 2006;374: 153-162. (Pubitemid 44819249)
5. Bailey MA, Mullins JJ, Kenyon CJ. Mineralocorticoid and glucocorticoid receptors stimulate epithelial sodium channel activity in a mouse model of Cushing syndrome. Hypertension. 2009;54:890-896.
6. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, Miyoshi J, Takai Y, Fujita T. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14:1370-1376.
7. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 1988; 242:583-585. (Pubitemid 18263202)
8. Funder JW. Aldosterone and mineralocorticoid receptors in the cardiovascular system. Prog Cardiovasc Dis. 2010;52:393-400.
9. Stewart PM, Corrie JE, Shackleton CH, Edwards CR. Syndrome of apparent mineralocorticoid excess: a defect in the cortisol-cortisone shuttle. J Clin Invest. 1988;82:340-349. (Pubitemid 18262536)
10. Li A, Tedde R, Krozowski ZS, Pala A, Li KX, Shackleton CH, Mantero F, Palermo M, Stewart PM. Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess. Am J Hum Genet. 1998;63:370-379. (Pubitemid 30418618)
11. Ulick S, Tedde R, Mantero F. Pathogenesis of the type 2 variant of the syndrome of apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1990;70:200-206.
12. Agarwal AK, Giacchetti G, Lavery G, Nikkila H, Palermo M, Ricketts M, McTernan C, Bianchi G, Manunta P, Strazzullo P, Mantero F, White PC, Stewart PM. CA-Repeat polymorphism in intron 1 of HSD11B2: effects on gene expression and salt sensitivity. Hypertension. 2000;36:187-194. (Pubitemid 30626987)
13. Alikhani-Koupaei R, Fouladkou F, Fustier P, Cenni B, Sharma AM, Deter HC, Frey BM, Frey FJ. Identification of polymorphisms in the human 11-hydroxysteroid dehydrogenase type 2 gene promoter: functional characterization and relevance for salt sensitivity. FASEB J. 2007;21: 3618-3628. (Pubitemid 350075151)
14. Carvajal CA, Romero DG, Mosso LM, Gonzalez AA, Campino C, Montero J, Fardella CE. Biochemical and genetic characterization of 11-hydroxysteroid dehydrogenase type 2 in low-renin essential hypertensives. J Hypertens. 2005;23:71-77. (Pubitemid 40128983)
15. Lovati E, Ferrari P, Dick B, Jostarndt K, Frey BM, Frey FJ, Schorr U, Sharma AM. Molecular basis of human salt sensitivity: the role of the 11-hydroxysteroid dehydrogenase type 2. J Clin Endocrinol Metab. 1999;84:3745-3749. (Pubitemid 30645235)
16. Mariniello B, Ronconi V, Sardu C, Pagliericcio A, Galletti F, Strazzullo P, Palermo M, Boscaro M, Stewart PM, Mantero F, Giacchetti G. Analysis of the 11-hydroxysteroid dehydrogenase type 2 gene (HSD11B2) in human essential hypertension. Am J Hypertens. 2005;18:1091-1098. (Pubitemid 41139908)
17. Poch E, Gonzalez D, Giner V, Bragulat E, Coca A, De La Sierra A. Molecular basis of salt sensitivity in human hypertension: evaluation of renin-angiotensin-aldosterone system gene polymorphisms. Hypertension. 2001;38: 1204-1209. (Pubitemid 34252832)
18. Watson B Jr, Bergman SM, Myracle A, Callen DF, Acton RT, Warnock DG. Genetic association of 11-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks. Hypertension. 1996;28:478-482. (Pubitemid 26296054)
19. Bailey MA, Paterson JM, Hadoke PW, Wrobel N, Bellamy CO, Brownstein DG, Seckl JR, Mullins JJ. A switch in the mechanism of hypertension in the syndrome of apparent mineralocorticoid excess. J Am Soc Nephrol. 2008;19:47-58.
20. Kotelevtsev Y, Brown RW, Fleming S, Kenyon C, Edwards CR, Seckl JR, Mullins JJ. Hypertension in mice lacking 11-hydroxysteroid dehydrogenase type 2. J Clin Invest. 1999;103:683-689. (Pubitemid 29122421)
21. Stewart PM, Murry BA, Mason JI. Human kidney 11-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotidedependent enzyme and differs from the cloned type I isoform. J Clin Endocrinol Metab. 1994;79:480-484.
22. Al-Dujaili EA, Mullins LJ, Bailey MA, Andrew R, Kenyon CJ. Physiological and pathophysiological applications of sensitive ELISA methods for urinary deoxycorticosterone and corticosterone in rodents. Steroids. 2009;74:938-944.
23. Farese RV Jr, Biglieri EG, Shackleton CH, Irony I, Gomez-Fontes R. Licorice-induced hypermineralocorticoidism. N Engl J Med. 1991;325: 1223-1227.
24. Lavery GG, Ronconi V, Draper N, Rabbitt EH, Lyons V, Chapman KE, Walker EA, McTernan CL, Giacchetti G, Mantero F, Seckl JR, Edwards CR, Connell JM, Hewison M, Stewart PM. Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. Hypertension. 2003;42:123-129. (Pubitemid 36944584)
25. Li A, Li KX, Marui S, Krozowski ZS, Batista MC, Whorwood CB, Arnhold IJ, Shackleton CH, Mendonca BB, Stewart PM. Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state. J Hypertens. 1997;15:1397-1402. (Pubitemid 28039566)
26. Henschkowski J, Stuck AE, Frey BM, Gillmann G, Dick B, Frey FJ, Mohaupt MG. Age-dependent decrease in 11-hydroxysteroid dehydrogenase type 2 activity in hypertensive patients. Am J Hypertens. 2008; 21:644-649. (Pubitemid 351733361)
27. Brem AS, Bina RB, King T, Chobanian MC, Morris DJ. Influence of dietary sodium on the renal isoforms of 11-hydroxysteroid dehydrogenase. Proc Soc Exp Biol Med. 1997;214:340-345.
28. Kerstens MN, Van der Kleij FG, Boonstra AH, Sluiter WJ, Koerts J, Navis G, Dullaart RP. Salt loading affects cortisol metabolism in normotensive subjects: relationships with salt sensitivity. J Clin Endocrinol Metab. 2003;88:4180-4185. (Pubitemid 37153718)
29. Liu Y, Singh RJ, Usa K, Netzel BC, Liang M. Renal medullary 11-hydroxysteroid dehydrogenase type 1 in Dahl salt-sensitive hypertension. Physiol Genomics. 2008;36:52-58.
30. Weber CS, Thayer JF, Rudat M, Sharma AM, Perschel FH, Buchholz K, Deter HC. Salt-sensitive men show reduced heart rate variability, lower norepinephrine and enhanced cortisol during mental stress. J Hum Hypertens. 2008;22:423-431. (Pubitemid 351712389)
31. Gaeggeler HP, Gonzalez-Rodriguez E, Jaeger NF, Loffing-Cueni D, Norregaard R, Loffing J, Horisberger JD, Rossier BC. Mineralocorticoid versus glucocorticoid receptor occupancy mediating aldosteronestimulated sodium transport in a novel renal cell line. J Am Soc Nephrol. 2005;16:878-891. (Pubitemid 41710298)
32. Ackermann D, Gresko N, Carrel M, Loffing-Cueni D, Habermehl D, Gomez-Sanchez CE, Rossier BC, Loffing J. In vivo nuclear translocation of mineralocorticoid and glucocorticoid receptors in rat kidney: differential effect of corticosteroids along the distal tubule. Am J Physiol Renal Physiol. 2010;299:F1473-F1485.
33. Wallerath T, Witte K, Schafer SC, Schwarz PM, Prellwitz W, Wohlfart P, Kleinert H, Lehr HA, Lemmer B, Forstermann U. Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sci USA. 1999; 96:13357-13362.
34. Liu Y, Mladinov D, Pietrusz JL, Usa K, Liang M. Glucocorticoid response elements and 11-hydroxysteroid dehydrogenases in the regulation of endothelial nitric oxide synthase expression. Cardiovasc Res. 2009;81:140-147.
35. Gomez-Sanchez EP, Gomez-Sanchez CE. Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. Am J Physiol. 1992;263: E1125-E1130. (Pubitemid 23024456)
36. Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ. 2009;339:b4567.